Activities as diverse as migration, proliferation and patterning occur simultaneously and in a coordinated fashion during tissue morphogenesis. In the growing vasculature, the formation of motile, invasive and filopodia-carrying endothelial sprouts is balanced with the stabilization of blood-transporting vessels. Here, we show that sprouting endothelial cells in the retina have high rates of VEGF uptake, VEGF receptor endocytosis and turnover. These internalization processes are opposed by atypical protein kinase C activity in more stable and mature vessels. aPKC phosphorylates Dab2, a clathrin-associated sorting protein that, together with the transmembrane protein ephrin-B2 and the cell polarity regulator PAR-3, enables VEGF receptor endocytosis and downstream signal transduction. Accordingly, VEGF receptor internalization and the angiogenic growth of vascular beds are defective in loss-of-function mice lacking key components of this regulatory pathway. Our work uncovers how vessel growth is dynamically controlled by local VEGF receptor endocytosis and the activity of cell polarity proteins.
terconvertible phenotypes and constant competition of endothelial cells for the tip position 6, 8 . This process involves the Notch pathway, which is thought to downregulate VEGF receptor expression and is therefore presumably less active in tip cells [9] [10] [11] . Another cell-contact-dependent signalling molecule, the Eph receptor ligand ephrin-B2 (encoded by the Efnb2 gene), promotes the invasive behaviour of endothelial cells and is required for normal VEGF receptor endocytosis and signalling [12] [13] [14] . Physiological angiogenesis also involves the gradual conversion of growing vessels into a stable and mature tubular network, in which endothelial cells are increasingly quiescent, show a phalanx-like morphology and are devoid of VEGF-induced activities such as the extension of filopodia or proliferation 15 . The postnatal vascularization of the retina in the mouse is an excellent model system for angiogenic sprouting and maturation, because sequentially occurring processes are spatially separated and can be imaged at high resolution 16 . Tip-and stalk-cellcontaining sprouts can be found at the peripheral edge of the growing vascular plexus next to VEGF-producing tissue regions, whereas the previously established, more mature vessels are located in the central retina.
Here, we show that angiogenesis is controlled by spatially regulated endothelial endocytosis. We identify Disabled 2 (Dab2), a clathrin-associated sorting protein (CLASP; ref. 17) , and the cell polarity protein PAR-3 as interaction partners of ephrin-B2 and VEGF receptors. These proteins mediate VEGF receptor endocytosis, which is negatively regulated by atypical protein kinase C (aPKC), another component of the PAR polarity complex. aPKC phosphorylates Dab2 and reduces the interaction between the CLASP and its cargo. We propose that spatially controlled activity of aPKC, which is high in established vessels but low in endothelial sprouts, critically contributes to important regional differences in VEGF receptor endocytosis, turnover and signalling.
RESULTS

Vessel beds exhibit spatial differences in VEGF receptor turnover
Previous work has provided evidence for high VEGF receptor transcript levels in the endothelial cells at the peripheral edge (angiogenic front) of the growing retinal vasculature, which is consistent with models linking VEGF gradients to strong VEGF receptor expression, the activation of endothelial sprouting and the induction of filopodium-extending tip cells 16, 18 . However, VEGFR2 and VEGFR3 immunostaining of the retinal vasculature at postnatal day 6 (P6) did not selectively label sprouting endothelial cells. Anti-VEGFR3 signals showed the previously published differences between arteries and veins ( Fig. 1a,b ; ref. 19 ), but were not predominantly associated with vessel sprouts (Fig. 1a and Supplementary Fig. S1a ). Even more surprisingly, immunosignals for the cytoplasmic region of VEGFR2 were almost undetectable in angiogenic sprouts, whereas comparably strong staining labelled the more established vasculature of the central retina (Fig. 1a,d ). Confirming the specificity of these patterns, endothelial anti-VEGFR2 signal was absent from the retinal vasculature of endothelial-cellspecific and inducible VEGFR2 (Flk1 i EC ) loss-of-function mice (Fig. 1a) . Flk1 i EC vessels also showed weaker signals for VEGFR3, which is consistent with previous reports placing VEGFR2 activity upstream of VEGFR3 expression 19, 20 . We speculated that the surprisingly weak VEGFR2 immunoreactivity in sprouts might reflect rapid local turnover and, accordingly, low steady-state levels of this receptor. As previous reports have suggested that VEGFR2 in cultured cells can be degraded through proteasomeas well as lysosome-dependent pathways [21] [22] [23] , we intraocularly injected the proteasome inhibitors MG132 or MG115, the lysosome inhibitor chloroquine, or MiTMAB and dynasore, which are cell-permeable inhibitors of dynamin and endocytosis, into P6 pups. At 2 h after injection, VEGFR2 and VEGFR3 protein levels were strongly increased in angiogenic sprouts, whereas immunosignals were significantly less enhanced in the vasculature of the central retina (Fig. 1b-d and Supplementary Fig. S1a,b) . Indicating that this upregulation required new protein synthesis, no significant increases in VEGFR2 and VEGFR3 immunosignals were seen when proteasome inhibitors were co-administered with cycloheximide, a general inhibitor of protein translation (Fig. 1c,d and Supplementary Fig. S1b ). As even short-term inhibition of protein degradation might lead to the stabilization of hypoxia-inducible factor, a key regulator of VEGF expression, and thereby to potential indirect effects, we also validated that Flk1/Vegfr2 and Flt4/Vegfr3 transcript levels were not significantly altered in inhibitor-injected pups (Fig. 1e) .
As the data above suggested rapid turnover (that is, degradation and new synthesis) of VEGF receptors at the angiogenic growth front, we next wanted to examine whether this activity was exclusively controlled by local differences in the availability of VEGF growth factors. To visualize the spatial pattern of internalization processes, Alexa dye-coupled human VEGF-A (165 isoform) was administered by intraocular injection. From 45 min after injection onwards, accumulation of the labelled growth factor was observed in retinal endothelial cells (Fig. 2a and Supplementary Fig. S1c ). Strongly arguing that these signals corresponded to internalized VEGF, Alexa-labelled spots partially co-localized with EEA1, a marker of early endosomes, were frequently found in perinuclear localization, and were strongly reduced in samples in which endocytosis had been blocked by dynamin inhibition (Fig. 2a and Supplementary Fig. S1d ). Confirming that the uptake of Alexa dye-coupled VEGF-A was largely mediated by VEGFR2, signals in the vasculature were profoundly diminished in Flk1 i EC vessels (Fig. 2b) . Thus, spots of dye-labelled VEGF-A corresponded primarily to receptor-and dynamin-dependent internalization of the ligand, as we would expect for clathrin-mediated endocytosis of ligand-receptor complexes. Next, we examined the spatial distribution of the exogenous and therefore uniformly provided Alexa dye-coupled growth factors. At 10 min after intraocular injection, fluorescent VEGF-A and VEGF-C were widely distributed throughout the central and peripheral retina ( Supplementary Fig. S2a,b) . In contrast, 2 h after injection, VEGF-A or VEGF-C spots were predominantly associated with endothelial cells at the angiogenic front and only much weaker signals were visible in the central plexus ( Fig. 2c and Figs 5f and 7c for statistical analysis). Arguing against a major influence of matrixbinding motifs in the 165 isoform of VEGF-A in this distribution pattern, injection of the shorter 121 isoform also preferentially labelled endothelial cells at the angiogenic front ( Supplementary Fig. S2c ). The sum of these results indicates previously unappreciated spatial differences in VEGF/VEGF receptor internalization even when growth factors were presented uniformly and not in gradients or other patterns.
PAR-3 and Dab2 associate with VEGFRs and ephrin-B2
Previous work has shown that the Eph receptor ligand and transmembrane protein ephrin-B2 is an important regulator of VEGF receptor endocytosis and downstream signalling 12, 13 . To gain further insight into the underlying molecular mechanism, we isolated interaction partners of the cytoplasmic region of murine ephrin-B2 (cyto WT; residues 254-336) by pulldown from rat kidney lysate (Methods). Analysis of the eluted proteins by liquid chromatography with tandem mass spectrometry (LC-MS/MS) led to the identification of several components of the endocytosis machinery, including proteins of the AP2 clathrin adaptor complex, clathrin heavy polypeptide, the large GTPase dynamin 2, the motor protein myosin VI and Disabled-2 (Dab2), a clathrin-associated sorting protein 17 ( Fig. 3a ,b and Supplementary Fig. S3a,b ). The interaction with Dab2, which was chosen for further analysis because of its cargo-selective role in endocytosis, required the PDZ binding motif in ephrin-B2, which is essential for many of its functions 24 , and was abolished by the exchange of a single amino-acid residue at the carboxy-terminus (cyto VS; replacement of Val 336 by serine; Fig. 3c ). Since Dab2 does not contain a PDZ domain, we reasoned that its interaction with ephrin-B2 involves another protein acting as molecular scaffold. As it was previously reported that the PAR polarity complex regulates endocytosis 25, 26 and can interact with the B-class ligand ephrin-B1 (ref. 27 ), which has high homology with ephrin-B2, we examined the role of PAR-3. When lung lysate was incubated with recombinant proteins corresponding to different domains of PAR-3 ( Fig. 3d) , ephrin-B2, VEGFR2 and VEGFR3 were precipitated with the PDZ-domain-containing PAR-3-2N fragment. Ephrin-B2 and VEGFR2 interacted with the first PDZ domain and VEGFR3 mainly interacted with the third PDZ domain. In contrast, Dab2 bound to PAR-3-3N, a fragment that contains the aPKC-binding region (Fig. 3a,d ). The recognition of molecular cargo is mediated by the PTB domain of Dab2 (ref. 28) . Accordingly, VEGFR2 and VEGFR3 were precipitated with the recombinant Dab2 PTB domain from cultured mouse endothelial cells stimulated with VEGF-A or VEGF-C (Fig. 3e) . In lung lysate, endogenous VEGFR3 was also found associated with Dab2 and PAR-3 by immunoprecipitation, whereas the interaction of VEGFR3 with Dab2 was strongly diminished in endothelial-cell-specific inducible PAR-3 loss-of-function mice (Pard3 i EC ; Fig. 3f ). The stimulation with recombinant VEGF-C, which resembles the fully processed form of this ligand that can activate both VEGFR2 and VEGFR3 (ref. 29) , increased the association of immunoprecipitated VEGFR2 with VEGFR3 and the clathrin heavy chain, which was strongly diminished after siRNA-mediated knockdown of Dab2 expression (Fig. 3g ).
Angiogenesis and VEGF receptor internalization require Dab2 and PAR-3
Next, we examined the roles of Dab2 and PAR-3 in VEGF receptor internalization. While Alexa dye-coupled VEGF-A and VEGF-C were readily taken up by cultured mouse control endothelial cells, knockdown of Pard3 or Dab2 significantly decreased the perinuclear accumulation of VEGF-A and VEGF-C ( Fig. 4a-c) . Surface biotinylation experiments further confirmed that VEGF-C-induced internalization of VEGFR3 and VEGFR2 was impaired in Dab2 knockdown or Pard3 knockdown cells (Fig. 4d ,e). In line with previous reports showing that VEGF receptor internalization is required for the full activation of certain downstream signals 12, 13, 30 , VEGF-A-or VEGF-C-induced activation of the small GTPase Rac1 was markedly reduced in Dab2 knockdown or Pard3 knockdown endothelial cells (Fig. 4f) . Likewise, VEGF-A-or VEGF-C-induced activation of mitogen-activated protein kinase ERK1/2, a signal linked to endothelial cell proliferation 31 , was reduced in Dab2 or Pard3 knockdown cells, whereas no significant effect on AKT phosphorylation was observed ( Supplementary Fig. S4a-c) . VEGF stimulation also induced the phosphorylation of aPKC in control but not in Dab2 knockdown cells ( Supplementary Fig. S4b ). Further arguing for a link between VEGFR2 signalling and aPKC activation, phospho-aPKC staining was reduced in P6 Flk1 i EC retinal vessels ( Supplementary Fig. S4d ).
Because gene targeting of Dab2 or PAR-3 in the embryonic endothelium caused severe vascular defects ( Supplementary Fig. S5a , b and data not shown), we used inducible endothelial-cell-specific genetic models to characterize the function of the genes in the postnatal retinal vasculature, which is one of the most established systems for the analysis of sprouting angiogenesis 16 . Whole mount staining confirmed the expression of Dab2 or PAR-3 in the P6 control retinal vasculature without appreciable differences between central and peripheral vessels ( pronounced reductions in the size and complexity of the endothelial network, tip cell number, sprout length, number of filopodia and endothelial proliferation (Fig. 5a-d and Supplementary Fig. S5d ,e), which resembled defects previously reported for Efnb2 mutant mice 12, 13 . Linking these defects to altered VEGF receptor endocytosis, the uptake of intraocularly injected, Alexa dye-labelled VEGF-A or VEGF-C was significantly reduced in endothelial cells at the P6 Dab2 i EC or Moreover, VEGFR2 and VEGFR3 immunostaining was enhanced in mutant sprouts ( Supplementary Fig. S6a-c) . These changes probably do not reflect altered expression of the Flk1/Vegfr2 or Flt4/Vegfr3 genes, because transcript levels were not significantly altered in Dab2 i EC or Pard3 i EC mutant lung lysates (data not shown).
Negative regulation of VEGF receptor endocytosis by atypical PKC
The identification of Dab2 and PAR-3 as regulators of VEGF receptor endocytosis raised the question of whether their activity was constitutively induced by ligand binding or actively regulated. Indicating a role of the latter, atypical protein kinase C, namely PKCλ or PKCζ , effectively phosphorylated the Dab2 PTB protein fragment in vitro, which strongly reduced its interaction with VEGFR2 or VEGFR3 ( Fig. 6a and data not shown). Western blot analysis revealed Ser 24 at the border of the Dab2 PTB domain as one of the phosphorylation sites (Fig. 6a) , and, accordingly, blocking of endogenous aPKC in cultured mouse endothelial cells strongly reduced Ser 24 phosphorylation of Dab2 (Fig. 6b) . For functional studies, we generated inducible endothelial-cell-specific PKCλ loss-of-function mice (Prkci i EC ), in which gene inactivation was triggered at P1-P3. The amount of Dab2 co-immunoprecipitated with VEGFR3 from P6 Prkci i EC lung lysate was strongly increased when compared with control littermate samples (Fig. 6c) . Arguing further for a negative regulation of the Dab2-cargo interaction by aPKC, VEGFR3-associated Dab2 lacked detectable Ser 24 phosphorylation (Fig. 6c) . Surface biotinylation assays showed that inhibition of aPKC activity in cultured endothelial cells led to a significant acceleration of ligand-induced VEGFR2 and VEGFR3 internalization (Fig. 6d) . This was accompanied by increased VEGF-Aor VEGF-C-induced activation of mitogen-activated protein kinase ERK1/2 (Fig. 6e) , a signal linked to endothelial cell proliferation 31 . VEGF-A-induced proliferation was reduced in cultured Dab2 and Pard3 knockdown mouse endothelial cells (data not shown).
To gain insight into the spatial pattern of aPKC activity in vivo, we immunostained retinas with phospho-aPKC antibody. Supporting the validity of this approach, signals corresponding to total aPKC (PKCλ and PKCζ ) and activated aPKC (autophosphorylated at Thr 560 or Thr 403 in PKCλ) were strongly reduced in the retinal vasculature of endothelial-cell-specific Prkci i EC mutants (Fig. 6f and data not shown). Phospho-aPKC immunofluorescence showed striking regional differences in the retinal vasculature. While total aPKC staining decorated endothelial cells both at the angiogenic front and in peripheral sprouts (Fig. 6g) , phospho-Thr 560 and phospho-Thr 403 signals were very low in endothelial cells at the angiogenic front in comparison to the more established vessels of the central retina ( Fig. 6h and Supplementary Fig. S6d ). These findings suggested that higher aPKC activity in endothelial cells of the central retina might reduce ligand-induced VEGF receptor internalization preferentially in this area. Indeed, the accumulation of Alexa dye-labelled VEGF-A or VEGF-C was significantly increased in the endothelium of the Prkci i EC central plexus relative to control littermates (Fig. 7a-c) . In contrast, the uptake of labelled VEGFs was not significantly altered at the Prkci i EC angiogenic front (Fig. 7c) . To further investigate the role of aPKC as a negative regulator of VEGF receptor internalization, the uptake of Alexa-labelled VEGF-A in cultured endothelial cells was examined in a pulse-chase experiment involving 3 min of stimulation (pulse) followed by 15 min incubation in serum-free growth medium (chase). aPKC inhibitor-treated cells, but not vehicle-treated control endothelial cells, showed substantial VEGF-A uptake under these conditions ( Supplementary Fig. S7a,b) . Loss of PKCλ in the postnatal endothelium also led to changes in the immunostaining levels of VEGF receptors. VEGFR2 and VEGFR3 signals were significantly reduced in vessels of the central retina but not at the angiogenic front ( Supplementary Fig. S7c,d ). Moreover, 2 h after inhibition of protein degradation by intraocular injection of MG132, VEGFR2 levels in mutant central vessels were partially restored. Changes for VEGFR3 in the central retina of MG132-treated Prkci i EC mice, however, were not significant under the same conditions ( Supplementary Fig. S7c,d) .
Next, we investigated the morphological changes in the Prkci i EC retinal vasculature. The size and complexity of the endothelial network were reduced predominantly in the centre at P6, whereas tip cell number, sprout length and number of filopodia at the angiogenic front were not significantly altered (Fig. 7d-g ). Vessels in the central retina, the region of enhanced VEGF internalization, showed numerous ectopic sprouts, filopodium-extending tip cells and empty collagen IV matrix sleeves (Fig. 7d-g and Supplementary Fig. S8a,b) . The latter is a mark for retracted sprouts as well as collapsed, unstable vessels, which may explain the hypovascularity of the Prkci i EC central retinal vessel network despite enhanced sprouting. This defect is reminiscent of ephrin-B2 gain-of-function mice, in which the transgenic overexpression of the ligand in endothelial cells led to enhanced but unstable sprouting, the appearance of numerous empty collagen IV sleeves and hypovascularity 13 . Ectopic sprouting in the central retina of Prkci i EC mutants was suppressed by the simultaneous targeting of the Pard3 or Dab2 genes (Fig. 8a) . Furthermore, anti-VE-cadherin immunostaining of P6 Prkci i EC and Pard3 i EC retinas did not reveal appreciable differences between mutants and the corresponding control littermates ( Supplementary Fig. S8c,d) . Thus, whereas PAR-3 and PKCλ are likely to play numerous distinct roles in the vasculature, the disruption of endothelial cell-cell contacts is not an overt explanation for ectopic sprouting and filopodium formation in Prkci i EC mutants.
DISCUSSION
In angiogenesis, as well as many other morphogenetic processes, individual cells or groups from an initially homogeneous population acquire distinct behaviours but act collectively, which enables complex and highly coordinated biological tasks 4, 32 . At the edge (front) of the growing retinal vasculature, leading, filopodium-extending tip cells and endothelial proliferation promote the extension of the vessel network. Conversely, vessels in the central retina (and elsewhere at the end of development) acquire a quiescent and mature phenotype. Our results indicate that the differential regulation of surface receptor endocytosis might help to assign certain cells to specific functional roles. High rates of receptor turnover and signalling might be key features of cells that lead migrating cell clusters and therefore need to respond strongly and quickly to signals in their tissue environment. Such dynamic responses also require the rapid clearing of activated receptors, which might otherwise prevent necessary adjustments in the speed or direction of migration. Our data also suggest that the distinct behaviours of actively growing and maturing vessels are not exclusively controlled by the proximity of endothelial cells to tissue-derived angiogenic growth factors such as VEGFs, which are known to play important roles in vessel patterning. Instead, we propose here that the differential regulation of VEGF receptor endocytosis through ephrin-B2, Dab2, PAR-3 and aPKC helps to assign specific tasks to endothelial cells (Fig. 8b) .
Given the important role of aPKC activity in VEGF receptor endocytosis and signalling, it will be important to determine the relevant regulators that act further upstream. Of the numerous direct and indirect molecular interactions known, the association of the PAR-3/PAR-6/aPKC polarity complex with junctional proteins and, in particular, cadherin family cell adhesion molecules are noteworthy 33, 34 . Junctions in more established vessels have presumably higher stability and might sustain or recruit more complexes containing active aPKC. Indeed, phosphorylated aPKC was strongly reduced in cultured VE-cadherin-deficient endothelial cells 35 . In support of this observation, endothelial phospho-aPKC immunostaining was strongly reduced in the central retina of endothelial-cell-specific, inducible Cdh5 (VE-cadherin) mutant mice (Fig. 8c) . However, it has been also reported that the VE-cadherin-associated polarity complex lacks aPKC in cultured endothelial cells 36 , which could indicate an indirect connection between the cadherin and aPKC activation. VEGF signalling emerges as another upstream regulator of aPKC. VEGF-A stimulation increases phospho-aPKC levels 37 , but with a slower kinetics when compared with AKT or ERK phosphorylation ( Supplementary  Fig. S4b) , and phospho-aPKC immunosignals were reduced in Flk1 i EC vessels ( Supplementary Fig. S4d ). Thus, it is perfectly possible that VEGF receptor endocytosis and signalling involves a negative feedback loop, in which aPKC dynamically downregulates Dab2-dependent VEGFR2 and VEGFR3 internalization after a period of signalling. These two examples suggest that multiple upstream stimuli can control the activity of aPKCs and thereby potentially affect the spatial pattern of VEGF receptor endocytosis. It also needs to be considered that Dab2 and PAR complex proteins have numerous known cellular roles in addition to the regulation of VEGF receptors. Such functions might contribute to the mutant phenotypes reported here.
Alterations in the expression or activity of endocytosis regulators might be relevant in pathological conditions. The vasculature of tumours is often irregularly organized, tortuous and leaky 15, 38 , which has been linked to enhanced VEGF/VEGFR2 signalling. The PAR complex is also an important signalling hub in cancer that has been proposed to have tumour suppressor function. Accordingly, the loss of polarity genes is associated with hyperproliferation in Drosophila 39 . It should be worthwhile to address whether links between aPKC, the endocytic machinery and growth factor signalling might explain some of the altered properties of tumour cells and vessels. Moreover, Eph/ephrin family molecules, CLASPs and polarity proteins are expressed in a large variety of different cell types and tissues [40] [41] [42] and are likely to control a range of different biological processes. For example, it has been recently proposed that Dab2 controls bone morphogenetic protein signalling in the axial vein of early zebrafish embryos 43 . Thus, our findings might well be applicable to other organ systems, morphogenetic processes and receptor pathways.
METHODS
Methods and any associated references are available in the online version of the paper.
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METHODS
Intraocular injections. VEGF-A (ReliaTech, catalogue no 300-076) VEGF-A121
(ReliaTech, catalogue no 300-072) and VEGF-C (PeproTech, catalogue no 100-20C) were labelled with the Alexa Fluor 546 protein labelling kit (Invitrogen) according to the manufacturer's instructions. 600 nl of labelled VEGF-A (0.2 mg ml −1 ) together with 100 µM of MG132 (Sigma), labelled VEGF-C (0.2 mg ml −1 ), 100 µM of MG132, 100 µM of MG115 (Calbiochem), 300 µM of MiTMAB (Calbiochem), 200 µM of dynasore (Calbiochem) or 1 mM of chloroquine (InvivoGen) in PBS were injected into the vitreous humour using glass capillary pipettes with a micromanipulator (Drummond Scientific). For co-injection of proteasome inhibitors with 50 µg ml −1 of cycloheximide (Calbiochem), cycloheximide was injected 1 h before the proteasome inhibitors.
Quantitative PCR analysis. For the analysis of messenger RNA relative expression levels, total RNA from control and mutant retinas was isolated with the RNeasy Mini Kit (Qiagen), and 500 ng per reaction was used to generate cDNA with the SuperScript III first-strand synthesis system (Invitrogen) and oligo(dT) primers. Quantitative PCR with reverse transcription was carried out by using an ABI PRISM 7900HT sequence detection system. TaqMan gene expression assays for murine Gapdh, Vegfr3, Flt4 and Vegfa were used in combination with TaqMan Gene Expression Master Mix (Applied Biosystems). Gene expression was normalized to the endogenous Gapdh. Relative expression differences represent the average of results obtained for at least three independent animals per group. For each animal/complementary DNA, two separate quantitative PCR with reverse transcription plates were used, with duplicate reactions for each gene.
Affinity purification. Adult rat kidney cytosol, which was concentrated by ammonium sulphate precipitation, was loaded onto a glutathione-Sepharose (GE Healthcare) affinity column on which 6 nmol of GST, GST-ephrin-B2 cyto WT, or GST-ephrin-B2 cyto VS were immobilized. After washing the column three times with wash buffer (20 mM Tris-HCl at pH 7.4, 1 mM EDTA, 1 mM dithiothreitol) and three times with wash buffer containing 50 mM NaCl, bound proteins were eluted three times with wash buffer containing 500 mM NaCl. The first eluates were subjected to SDS-PAGE, and the isolated proteins were detected by silver staining, Western blot with anti-Dab2 antibodies (Santa Cruz, H-110, 1:500) or LC-MS/MS analysis. 48 . Images shown in the figures represent data obtained with Pdgfb-iCre transgenes unless indicated otherwise. Cre activity in newborn mice was induced by three consecutive intraperitoneal tamoxifen (1 mg ml −1 in ethanol/peanut oil) injections of 50 µl given on P1, P2 and P3. The phenotypes of mutant mice were analysed at postnatal stage P6, as indicated. There are no known sex-specific differences in retinal angiogenesis, which enabled us to combine male and female mice for analysis. Tamoxifen-injected Cre − littermate animals were used as controls.
All animal experiments were carried out in compliance with the relevant laws and institutional guidelines and were approved by local animal ethics committees.
HPLC and mass spectrometry. Peptides from affinity-purified proteins were prepared according to the filter aided sample preparation method 49 in combination with a further anion exchange fractionation step 50 . Reverse-phase nano-LC-MS/MS analysis of peptides was carried out using an EasyLC nanoflow LC system (Proxeon), which was coupled to an LTQ Orbitrap Velos mass spectrometer (Thermo Fisher Scientific) equipped with a nanoelectrospray source (Proxeon). Chromatographic separation of peptides was achieved on in house packed fused silica capillary columns (length 15 cm; internal diameter 75 µm) filled with reverse-phase ReproSilPur C18-AQ 3 µm resin (Maisch). Peptide mixtures were loaded at a maximum backpressure of 200 bar and then eluted with a linear gradient at a flow rate of 0.25 µl min −1 . The mass spectrometer was operated in the data-dependent mode to automatically measure MS and MS2. LTQ-FT full scan MS spectra (from m/z 350 to m/z 1,650) were acquired with a resolution of R = 60,000 at m/z 400. The 15 ions with most intense signal were isolated and fragmented in the linear ion trap by using collision-induced dissociation. Raw data files were converted to Mascot generic format files with MaxQuant v1.0. 13.13 (ref. 51) and the Mascot search engine (version 2.2.02) was used for database searches and protein identification (IPI 3.60 mouse). The search parameters were trypsin as cleavage reagent, a maximum of two missed cleavages and a minimum of six amino acids per peptide; carbamidomethylation of cysteine residues was set as a fixed modification and oxidation of methionines was selected as a variable modification. The maximum allowed mass deviation was 10 ppm for MS and 0.5 Da for MS/MS scans.
Immunoprecipitation. For immunoprecipitation of VEGFR2 and VEGFR3, 5-10 µg of antibodies (VEGFR2, R&D, AF644 and MAB4431; VEGFR3, R&D, AF743) were crosslinked to protein A/G Sepharose beads by using a Protein A/G HP SpinTrap Buffer kit (GE Healthcare) according to the manufacturer's instructions. For the co-immunoprecipitation of VEGFR2, VEGFR3 and the clathrin heavy chain (CHC), Efnb2 lox/lox cells 13 (1×10 6 cells per 10 cm dish) were seeded and incubated for 24 h. Before stimulation, cells were deprived of serum for 24 h. Cells were then incubated in serum-free growth medium containing 100 ng ml −1 of VEGF-C (Peprotech) at 37 • C for 5 min, washed with ice-cold PBS and lysed with 800 µl of lysis buffer (50 mM Tris-HCl at pH 7.4, 1% NP-40, 150 mM NaCl, protease inhibitor cocktail (Sigma, P2714, 1:100), phosphatase inhibitor cocktail (Calbiochem, 524629, 1:50)). The lysates were centrifuged at 20,000 g for 10 min at 4 • C, and supernatants were incubated with protein G Sepharose beads crosslinked to VEGFR3 antibody at 4 • C for 1 h. The beads were washed three times with an excess of lysis buffer and eluted with 60 µl of SDS sample solution. 20 µl of each eluate was subjected to SDS-PAGE, followed by immunoblotting with antibodies recognizing VEGFR3 (eBioscience, ALF4, 1:1,000), VEGFR2 (Cell Signaling, 55B11, 1:1,000) and CHC (Becton Dickinson, 610500, 1:1,000).
For immunoprecipitation of PAR-3, VEGFR3 and Dab2, P6 mouse lung lysates were generated with lysis buffer (50 mM Tris-HCl at pH 7.4, 0.1% SDS, 1% NP-40, 150 mM NaCl, protease inhibitor cocktail (Sigma, P2714, 1:100), phosphatase inhibitor cocktail (Calbiochem, 524629, 1:50)) and cleared by centrifugation at 100,000 g for 30 min at 4 • C. The soluble supernatants were incubated protein A/G Sepharose beads crosslinked to antibodies for 1 h at 4 • C, washed three times with wash buffer (50 mM Tris-HCl at pH 7.4, 1% NP-40, 150 mM NaCl, protease inhibitor cocktail (Sigma, P2714, 1:100), phosphatase inhibitor cocktail (Calbiochem, 524629, 1:50), and eluted by boiling in sample buffer for SDS-PAGE. Immunoblot analysis with the indicated antibodies was carried out. VEGF-A uptake in cultured cells. For Alexa-labelled VEGF-A uptake in cultured cells, control (Efnb2 lox/lox ) cells were seeded on cover slips at a density of 3.0×10 5 in 6 cm dishes and incubated for 24 h. After siRNA transfection, cells were deprived of serum for 24 h before they were incubated in serum-free growth medium containing 4 µg ml −1 of Alexa-labelled VEGF-A or VEGF-C at 37 • C for 30 min. For the pulse-chase analysis, serum-deprived cells were treated with 5 µM of aPKC inhibitor (Merck, 539624) for 30 min and stimulated with 4 µg ml −1 of Alexa-labelled VEGF-A for 3 min. After washing with serum-free growth medium, cells were further incubated for 15 min. Finally, cells were fixed with 4% PFA for 10 min on ice and stained with Alexa-coupled phalloidin (Invitrogen) and DAPI.
Pulldown assays. GST pulldown assay was carried out as previously described 52 . Briefly, GST-fusion proteins were immobilized on glutathione-Sepharose beads. The beads were incubated with Efnb2 lox/lox cells 13 or lung lysate. Beads were washed three times with lysis buffer (20 mM Tris-HCl at pH 7.4, 1 mM EDTA, 1 mM dithiothreitol, 150 mM NaCl and 1% NP-40, protease inhibitor cocktail (Sigma, P2714, 1:100)) and dissolved into SDS sample buffer. Bound proteins were subjected to Western blot analysis with anti-VEGFR2 (Cell Signaling, 55B11, 1:1,000), anti-VEGFR3 (eBioscience, ALF4, 1:1,000), anti-Dab2 (Santa Cruz, H-110, 1:500), or anti-ephrin-B2 antibodies (Sigma, HPA008999, 1:1,000). 
